呼吸道疾病疫苗市场－全球产业规模、份额、趋势、机会、预测：按类型、感染类型、分销管道、地区和竞争格局划分，2021-2031年

全球呼吸道疾病疫苗市场预计将从 2025 年的 956.9 亿美元成长到 2031 年的 1,024.9 亿美元，复合年增长率为 1.15%。

这些疫苗是一种旨在诱导人体对感染肺部和呼吸道的病原体（例如流感病毒、呼吸道融合细胞病毒和肺炎球菌）产生主动获得性免疫的生物製药。该领域的成长主要得益于全球老年人口的不断增加，他们容易罹患严重的呼吸系统疾病，以及全球感染疾病负担的日益加重。此外，各国政府在医疗保健免疫倡议的大量投入以及支持快速核准的法规结构也积极推动了市场扩张。正如国际药品製造商协会联合会（IFPMA）在2024年指出的那样，目前在开发平臺疫苗超过285种，这凸显了该行业致力于应对感染疾病风险的坚定决心。

儘管存在这些成长要素，但由于低温运输配送相关的复杂物流要求，市场仍面临许多障碍。在发展中地区，维持整个供应链的温度控制是一项挑战，这限制了市场覆盖范围，并增加了产品劣化的风险。这些物流限制阻碍了新兴市场的进入，并妨碍了製造商充分利用全球对先进呼吸系统免疫解决方案的需求。

市场驱动因素

创新呼吸道合胞病毒（RSV）和肺炎球菌疫苗的快速商业化显着扩大了市场，尤其是在老年人群体中。首个老年人RSV疫苗的核准填补了医疗保健领域的关键空白，并促成了产品的快速普及。这种使用量的增加为生产商带来了盈利的收入，并凸显了解决老龄化呼吸道疾病易感性问题的商业性潜力。例如，葛兰素史克（GSK）在其「2023年全年及第四季」报告中指出，其Alexby疫苗上市首年销售额达到12亿英镑，显示这些新型预防措施具有巨大的市场价值。这个新类别的成功建立正在增强主要行业参与者的整体财务稳定性。赛诺菲在2024年2月发布的新闻稿也印证了这一点，新闻稿称，其呼吸道和免疫产品组合的年度疫苗总销售额已达75亿欧元。

同时，mRNA和重组蛋白技术的快速发展正在彻底改变疫苗的研发和生产。各公司正优先利用这些高度灵活的平台来设计多价候选疫苗，以期透过单剂接种即可抵御多种威胁，例如流感和新冠肺炎。这种向先进技术模式的策略转变需要对临床试验进行大量投资，以验证疫苗的有效性并改善给药方法。根据Moderna公司于2024年2月发布的“2023财年第四季度及全年财务业绩报告”，其研发支出增至48亿美元。这一增长主要得益于该公司呼吸系统疾病疫苗和联合疫苗研发计划的后期临床试验。此类投资凸显了疫苗产业利用灵活平台来减轻季节性病毒影响并加强应对疫情准备的决心。

市场挑战

低温运输配送所需的复杂物流对全球呼吸道疾病疫苗市场的扩张构成重大障碍。呼吸道疫苗，尤其是流感和肺炎球菌疾病的疫苗，属于生物活性极低的疫苗，需要从生产到接种全程冷藏。许多新兴经济体缺乏维持这种严格温度控制的基础设施，增加了产品劣化和效力降低的风险。这种物流方面的不足给生产商带来了高昂的营运成本和技术挑战，阻碍了供应链向需求旺盛但基础设施欠发达地区的扩张。因此，无法保证产品品质成为直接的市场准入壁垒，有效缩小了先进免疫疗法的潜在市场。

开发中国家市场渗透率持续存在的差距凸显了这项挑战的严峻性。根据全球疫苗免疫联盟（Gavi）2024年的报告，低收入国家仍有约1,020万儿童未接种疫苗，显示维持有效的供应链，并向偏远社区提供疫苗，仍然困难重重。如此巨大的疫苗覆盖不足清楚地表明，物流限制和低温运输中断如何直接阻碍了疫苗行业满足全球需求的能力，阻碍了收入成长和市场多元化。

市场趋势

孕期免疫接种的策略转变正在改变全球呼吸道疾病疫苗市场，填补了婴幼儿群体中直接接种疫苗困难所导致的关键免疫缺口。製药公司正日益关注孕期接种的疫苗，这些疫苗能够透过胎盘传递保护性抗体，尤其是针对呼吸道融合细胞病毒（RSV）的疫苗。这种方法能够有效降低新生儿严重下呼吸道感染疾病的发生率，而此类感染历来导致较高的住院率。儘管存在季节性波动，但已通过核准的孕期疫苗配方仍持续被市场接受，这证明了该策略的商业性成功。根据辉瑞公司2025年11月发布的「2025年第三季业绩强劲」新闻稿，该公司旗下的Ablisvo疫苗第三季全球销售额达2.79亿美元，凸显了市场对扩大免疫覆盖范围（包括怀孕保护）的需求。

同时，通用流感疫苗候选药物的研发正在稳步推进，这是克服季节性病毒株不匹配挑战的关键一步。科学家不再局限于设计针对特定病毒株的疫苗，而是将目标转向保守的病毒表位，例如血凝素茎，旨在实现对多种流感亚型的广泛且持久的免疫力。这一趋势的特点是，旨在提供多季保护并降低流感大流行威胁的新一代候选疫苗的临床试验数量正在增加。根据明尼苏达大学感染疾病研究与政策中心（CIDRAP）发布的《通用流感疫苗技术趋势更新（2025年11月）》，美国国家过敏症和感染疾病研究所（NIAID）正在支持启动两种具有广谱功效的新型流感疫苗候选药物的二期临床试验，这表明开发平臺已相当成熟。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球呼吸系统疾病疫苗市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 种类别（ウイルスワクチン、细菌ワクチン、复合ワクチン）
  • 按类型分類的感染疾病（COVID-19、流感、呼吸道融合细胞病毒(RSV)、肺炎、其他）
  • 分销通路（医院/零售药局、政府供应商、其他）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第6章 北米の呼吸器疾患ワクチン市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲呼吸系统疾病疫苗市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第8章 アジア太平洋地域の呼吸器疾患ワクチン市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲呼吸系统疾病疫苗市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲呼吸系统疾病疫苗市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章 全球呼吸系统疾病疫苗市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• GSK plc.
• Johnson & Johnson Services, Inc.
• Pfizer Inc.
• Sanofi SA
• Serum Institute of India Pvt. Ltd.
• SINOVAC Biotech Ltd.
• Bavarian Nordic A/S
• Merck & Co., Inc.
• AstraZeneca Plc.
• Moderna Inc

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Respiratory Disease Vaccine Market is projected to expand from a valuation of USD 95.69 Billion in 2025 to USD 102.49 Billion by 2031, reflecting a compound annual growth rate of 1.15%. These vaccines are immunobiological formulations intended to induce active acquired immunity against pathogens that infect the lungs and airways, such as influenza, respiratory syncytial virus, and pneumococcal bacteria. Growth in this sector is largely propelled by an increasing global elderly population prone to severe respiratory issues, alongside the growing burden of infectious diseases worldwide. Additionally, substantial government spending on healthcare immunization initiatives and supportive regulatory frameworks for faster approvals actively encourage market expansion. As noted by the International Federation of Pharmaceutical Manufacturers and Associations in 2024, the development pipeline contained over 285 vaccine candidates, highlighting significant industrial commitment to combating infectious health risks.

Despite these positive growth factors, the market encounters a major hurdle due to the intricate logistics necessitated by cold chain distribution. Ensuring consistent temperature regulation across the supply chain poses a challenge in developing areas, which restricts market reach and raises the likelihood of product spoilage. This logistical limitation establishes a barrier to entry in emerging markets and hampers manufacturers' capacity to fully leverage the global demand for sophisticated respiratory immunization solutions.

Market Driver

The rapid commercialization of innovative RSV and pneumococcal vaccines has substantially broadened the market, especially within the elderly demographic. The recent authorization of first-in-class RSV vaccines for older adults has addressed a significant void in preventative healthcare, leading to prompt and extensive product adoption. This increase in utilization has generated a profitable revenue channel for manufacturers, confirming the commercial potential of addressing age-related respiratory susceptibilities. For example, GSK reported in its "Full-year and fourth quarter 2023" document that its Arexvy vaccine achieved sales of £1.2 billion in its debut year, illustrating the immense market value of these new prophylactic measures. This successful establishment of a new category bolsters the overall financial stability of leading industry participants, as evidenced by Sanofi's February 2024 press release stating that total vaccine sales hit €7.5 billion for the year, propelled by their advancing respiratory and immunization portfolio.

At the same time, the swift uptake of mRNA and recombinant protein technologies is revolutionizing the terrain of vaccine creation and manufacturing. Firms are prioritizing these adaptable platforms to design multivalent candidates that can combat simultaneous threats, such as influenza and COVID-19, in a single dose. This strategic shift towards sophisticated modalities necessitates heavy investment in clinical trials to confirm effectiveness and refine delivery methods. According to Moderna's "Fourth Quarter and Fiscal Year 2023 Financial Results" from February 2024, research and development spending rose to $4.8 billion, an increase primarily driven by late-stage trials for their respiratory and combination vaccine initiatives. Such financial dedication highlights the industry's determination to utilize flexible platforms to alleviate seasonal viral impacts and improve pandemic preparedness.

Market Challenge

The intricate logistics demanded by cold chain distribution present a significant barrier to the expansion of the Global Respiratory Disease Vaccine Market. Respiratory vaccines, especially those designed for influenza and pneumococcal bacteria, are biologically delicate items that require continuous refrigeration from production through to administration. In numerous emerging economies, the infrastructure needed to maintain this rigorous temperature control is often insufficient, resulting in an increased danger of product deterioration and loss of potency. This logistical weakness compels manufacturers to face higher operational expenses and technical challenges, which deters the extension of supply chains into regions with high demand but poor infrastructure. Consequently, the inability to assure product quality serves as a direct obstacle to entry, effectively diminishing the potential market for advanced immunization therapies.

The gravity of this challenge is highlighted by the enduring disparity in market penetration within developing countries. As reported by Gavi, the Vaccine Alliance in 2024, there were roughly 10.2 million zero-dose children in lower-income nations, a statistic that underscores the ongoing difficulty in sustaining functional supply chains required to deliver effective vaccines to isolated populations. This large volume of unreached people illustrates how logistical constraints and cold chain breakdowns directly impede the industry's capacity to meet global demand, thereby hindering revenue expansion and market diversification.

Market Trends

The strategic movement towards maternal immunization is transforming the Global Respiratory Disease Vaccine Market by filling the critical immunity void in infants too young for direct vaccination. Pharmaceutical companies are increasingly concentrating on vaccines given during pregnancy to enable the transfer of protective antibodies across the placenta, specifically targeting respiratory syncytial virus (RSV). This method effectively lowers the incidence of severe lower respiratory tract infections in newborns, a group historically prone to high rates of hospitalization. The commercial success of this strategy is demonstrated by the continued uptake of approved maternal formulations despite seasonal variations. As per Pfizer's "Pfizer Reports Solid Third-Quarter 2025 Results" press release from November 2025, the company's Abrysvo vaccine brought in $279 million in global revenue during the third quarter, confirming the market desire to broaden immunization scope to include maternal protection.

Simultaneously, the development of universal influenza vaccine candidates marks a crucial step forward intended to surmount the issues of seasonal strain mismatches. Scientists are advancing beyond strain-specific designs to target conserved viral epitopes, like the hemagglutinin stalk, aiming to deliver broad-spectrum and long-lasting immunity against various influenza subtypes. This trend is defined by an increase in the clinical testing of next-generation candidates engineered to provide multi-season defense and reduce pandemic threats. According to the "November 2025 updates to the Universal Influenza Vaccine Technology Landscape" report by the University of Minnesota's Center for Infectious Disease Research and Policy, the National Institute of Allergy and Infectious Diseases (NIAID) backed the launch of two new Phase 2 clinical trials for broadly protective influenza vaccine candidates, indicating a substantial maturation of the development pipeline.

Key Market Players

• GSK plc.
• Johnson & Johnson Services, Inc.
• Pfizer Inc.
• Sanofi SA
• Serum Institute of India Pvt. Ltd.
• SINOVAC Biotech Ltd.
• Bavarian Nordic A/S
• Merck & Co., Inc.
• AstraZeneca Plc.
• Moderna Inc

Report Scope

In this report, the Global Respiratory Disease Vaccine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Respiratory Disease Vaccine Market, By Type

• Viral Vaccine
• Bacterial Vaccine
• Combination Vaccine

Respiratory Disease Vaccine Market, By Infection

• COVID-19
• Influenza
• Respiratory Syncytial Virus (RSV)
• Pneumonia
• Others

Respiratory Disease Vaccine Market, By Distribution Channel

• Hospital & Retail Pharmacies
• Government Suppliers
• Others

Respiratory Disease Vaccine Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Respiratory Disease Vaccine Market.

Available Customizations:

Global Respiratory Disease Vaccine Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Respiratory Disease Vaccine Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Viral Vaccine, Bacterial Vaccine, Combination Vaccine)
  • 5.2.2. By Infection (COVID-19, Influenza, Respiratory Syncytial Virus (RSV), Pneumonia, Others)
  • 5.2.3. By Distribution Channel (Hospital & Retail Pharmacies, Government Suppliers, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Respiratory Disease Vaccine Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Infection
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Respiratory Disease Vaccine Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Infection
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Respiratory Disease Vaccine Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Infection
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Respiratory Disease Vaccine Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Infection
      • 6.3.3.2.3. By Distribution Channel

7. Europe Respiratory Disease Vaccine Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Infection
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Respiratory Disease Vaccine Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Infection
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. France Respiratory Disease Vaccine Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Infection
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Respiratory Disease Vaccine Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Infection
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Respiratory Disease Vaccine Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Infection
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Respiratory Disease Vaccine Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Infection
      • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Respiratory Disease Vaccine Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Infection
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Respiratory Disease Vaccine Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Infection
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Respiratory Disease Vaccine Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Infection
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Japan Respiratory Disease Vaccine Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Infection
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. South Korea Respiratory Disease Vaccine Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Infection
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Respiratory Disease Vaccine Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Infection
      • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Respiratory Disease Vaccine Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Infection
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Respiratory Disease Vaccine Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Infection
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. UAE Respiratory Disease Vaccine Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Infection
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. South Africa Respiratory Disease Vaccine Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Infection
      • 9.3.3.2.3. By Distribution Channel

10. South America Respiratory Disease Vaccine Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Infection
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Respiratory Disease Vaccine Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Infection
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Colombia Respiratory Disease Vaccine Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Infection
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. Argentina Respiratory Disease Vaccine Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Infection
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Respiratory Disease Vaccine Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. GSK plc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Johnson & Johnson Services, Inc.
• 15.3. Pfizer Inc.
• 15.4. Sanofi SA
• 15.5. Serum Institute of India Pvt. Ltd.
• 15.6. SINOVAC Biotech Ltd.
• 15.7. Bavarian Nordic A/S
• 15.8. Merck & Co., Inc.
• 15.9. AstraZeneca Plc.
• 15.10. Moderna Inc

16. Strategic Recommendations

17. About Us & Disclaimer